Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

01.06.21

EyeGate Enters Into Agreement for $8.0 Million Private Placement

WALTHAM, MA, January 06, 2021 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company developing and commercializing products for treating inflammatory and immune diseases with a focus on the...
Read more
12.21.20

EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma

WALTHAM, MA, December 21, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical stage company focused on developing products for treating disorders of the eye,...
Read more
11.09.20

EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update

WALTHAM, MA, November 9, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced...
Read more
09.08.20

EyeGate Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference

WALTHAM, MA, September 8th, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
08.12.20

EyeGate Pharma Confirms Path Forward with FDA To Develop Combination Product

WALTHAM, MA, August 12, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
08.06.20

EyeGate Pharma Reports Second Quarter 2020 Financial Results and Provides Business Update

WALTHAM, MA, August 6, 2020 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced...
Read more
07.14.20

EyeGate Pharma to Proceed with PE Pivotal Study

WALTHAM, MA, July 14, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
06.11.20

EyeGate Pharma Receives Positive Feedback from FDA Regarding Ocular Bandage Gel Packaging

WALTHAM, MA, June 11, 2020 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more